A Phase 1 interventional study of MK-8527 and CBZ in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time when MK-8527 is given alone and with the medication CBZ.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria include, but are not limited to:
Exclusion Criteria:
Exclusion criteria include, but are not limited to:
Has a history or presence of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A (Period 1): Participants will receive a single dose of MK-8527 on Day 1. Treatment B (Period 2): Participants will receive CBZ twice a day on Days 1 to 20 and a single dose of MK-8527 coadministered with the morning dose of CBZ on Day 14. A washout period will separate Treatments A and B.
Drug: MK-8527 · Drug: CBZ
Oral Tablet
Oral Extended-release Capsule
Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of MK-8527
Blood samples will be collected to determine the AUC0-inf of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Area Under the Concentration-Time Curve from 0 to the Time of the Last Quantifiable Sample (AUC0-last) of MK-8527
Blood samples will be collected to determine the AUC0-last of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-8527
Blood samples will be collected to determine the AUC0-24 of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 24 hours postdose)
Area Under the Concentration-Time Curve from 0 to 168 hours (AUC0-168) of MK-8527
Blood samples will be collected to determine the AUC0-168 of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Maximum Observed Plasma Concentration (Cmax) of MK-8527
Blood samples will be collected to determine the Cmax of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Time to Maximum Observed Plasma Concentration (Tmax) of MK-8527
Blood samples will be collected to determine the Tmax of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Apparent Terminal Half-Life (t1/2) of MK-8527
Blood samples will be collected to determine the t1/2 of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Apparent Clearance (CL/F) of MK-8527
Blood samples will be collected to determine the CL/F of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527
Blood samples will be collected to determine the Vz/F of MK-8527 in plasma
Time frame: Predose and at designated timepoints (up to 168 hours postdose)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 60 days
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 30 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Apr 2025 to primary completion in Jun 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alimatravir